Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes-Reference-Cited by-同舟云学术

Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes

Published:2008-11 Issue:22 Volume:52 Page:1758-1768
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Pinto Duane S.,Stone Gregg W.,Shi Chunxue,Dunn Elizabeth S.,Reynolds Matthew R.,York Meghan,Walczak Joshua,Berezin Ronna H.,Mehran Roxana,McLaurin Brent T.,Cox David A.,Ohman E. Magnus,Lincoff A. Michael,Cohen David J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. Bivalirudin for patients with acute coronary syndromes;Stone;N Engl J Med,2006

2. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale;Stone;Am Heart J,2004

3. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

4. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial;Cohen;Circulation,1995

5. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials;Taira;Am Heart J,2003

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures;Journal of Vascular Surgery;2019-07

2. Economic Considerations for Complex Mixture Drugs;The Science and Regulations of Naturally Derived Complex Drugs;2019

3. Transulnar versus transradial access as a default strategy for percutaneous coronary intervention;Heart Views;2019

4. Reversing the “Risk‐Treatment Paradox” of Bleeding in Patients Undergoing Percutaneous Coronary Intervention: Risk‐Concordant Use of Bleeding Avoidance Strategies Is Associated With Reduced Bleeding and Lower Costs;Journal of the American Heart Association;2018-11-06

5. Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?;Journal of Thoracic Disease;2018-01